H,,,let me get this straight...We have the coverage of analyst that stake their, and their company's
reputation on being more right than wrong..and they willingly identify themselves by first and last
name, complete with an address, and if you wish a phone number. These highly educated, and
widely followed professional analyst all in unison agree that the news this week was both compelling
and advances the arguement that this drug will be a success. But we, on the other hand have a
couple ( could be one) board poster that posts message after message, many of which are
clearly fraudulent, that this whole endeavor is failure. Now we don't know their true names, and
we don't know their positions, but we should just blindly follow them because? let me repeat that..?
The volume this week is speaking volumes itself..shares are being shook loose, but someone
is buying them all up....wonder why? Oh...now it's starting to make sense...
zake1 - we can disagree,but Analysts and clowns - high risk going forward
The stupid posts by fudfighter4 and the usual suspects belie reality and investor sentiment.
The results were disappointing is true- the trial met the primary endpoint of being not as good as TOBI - yippie!
The adverse affects were smoothed over by Will Lewis who did an exemplary job of speaking to Arikaces advantages for CF patients.( duration, but competitor TIP is cheaper,effective and approved)
Investors know that the regulatory pathway investor sentiment company finances were all lowered going forward,.CF in Europe in a couple of years is a minimal marketing victory imho- I predict it will not get first tier coverage in socialized medicine govt and drug coverage.
The risks are much higher now - dilution delays are just 2 possibilities that should give all caution.The clowns will post out of theirass to make themselves feel good. My ignore and trading will continue on Monday